Cor Vasa 2021, 63(3):373-377 | DOI: 10.33678/cor.2021.084

(Type 2 diabetes and heart failure - how to optimize cooperation of cardiologist and diabetologist)

Markéta Kubíčkováa, Josef Bisb
a Diabetologické centrum, III. interní gerontometabolická klinika, Fakultní nemocnice Hradec Králové, Hradec Králové
b Kardiocentrum, I. interní kardioangiologická klinika, Fakultní nemocnice Hradec Králové, Hradec Králové

Heart failure and type 2 diabetes mellitus often occur together and are associated with poor prognosis and high mortality. Cardiovascular studies with SGLT2 inhibition carried out in recent years in type 2 diabetics have shown its beneficial effect on the reduction of hospitalization for heart failure. This beneficial effect demonstrated with all gliflozins (empagliflozin, dapagliflozin, canagliflozin) became the subject of further research and thus hope for the treatment of heart failure. DAPA-HF studies with dapagliflozin aimed at patients with chronic heart failure and reduced EF (HFrEF) confirmed a decrease in hospitalization for heart failure and a decrease in cardiovascular and overall mortality in patients treated with dapagliflozin regardless of the presence of diabetes. Dapagliflozin is therefore not only an antidiabetic, but becomes also a useful drug for the treatment of the chronic heart failure with reduced EF.

Keywords: Cardioprotective effects, Chronic heart failure, Dapagliflozin, Nephroprotective effects, SGLT2 inhibition, Type 2 diabetes

Received: June 4, 2021; Revised: June 21, 2021; Accepted: June 22, 2021; Published: July 20, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kubíčková M, Bis J. (Type 2 diabetes and heart failure - how to optimize cooperation of cardiologist and diabetologist). Cor Vasa. 2021;63(3):373-377. doi: 10.33678/cor.2021.084.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cheng YJ, Imperatore G, Geiss LS, et al. Trends and Disparities in Cardiovascular Mortality Among U.S. Adults With and Without Self-Reported Diabetes, 1988-2015. Diabetes Care 2018;41:2306-2315. Go to original source... Go to PubMed...
    2. Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:853-872. Go to original source... Go to PubMed...
    3. Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699-703. Go to original source... Go to PubMed...
    4. Johansson I, Dahlström U, Edner M, et al. Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure, J Am Coll Cardiol 2016;68:1404-1416. Go to original source... Go to PubMed...
    5. Táborský M, Aiglová R, Lazárová M, et al. Beta-blockers utilization in heart failure patients: sub-analysis of a nation-wide population-based study in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2020;164:XX. Go to original source... Go to PubMed...
    6. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211-1259. Go to original source... Go to PubMed...
    7. Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review. Circulation 2016;133:187-225. Go to original source... Go to PubMed...
    8. Mamas MA, Sperrin M, Watson MC, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail 2017;19:1095-1104. Go to original source... Go to PubMed...
    9. Lovshin JA, Bjornstad P, Lovblom LE, et al. Atherosclerosis and microvascular complications: results from the Canadian Study of longevity in type 1 diabetes. Diabetes Care 2018;41:2570-2578. Go to original source... Go to PubMed...
    10. Wanner C, Marx N. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia 2018;61:2134-2139. Go to original source... Go to PubMed...
    11. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-130. Go to original source... Go to PubMed...
    12. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392:1519-1529. Go to original source... Go to PubMed...
    13. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322. Go to original source... Go to PubMed...
    14. Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844. Go to original source... Go to PubMed...
    15. Zinman B, Wanner CH, Lachin JM, et al. The EMPA-REG OUTCOME investigators: empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128. Go to original source... Go to PubMed...
    16. Neal B, Perkovic V, Mahaffey KV. The CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657. Go to original source... Go to PubMed...
    17. Clinicaltrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). Available from: https://clinicaltrials.gov/ct2/show/NCT01730534
    18. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New Engl J Med 2019;381:1995-2008. Go to original source... Go to PubMed...
    19. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436-1446. Go to original source... Go to PubMed...
    20. Glucose lowering medication in type 2 diabetes: 2021 ADA Professional Practice Committee Adaptation of Davies et al and Buse et al. Diabetes Care 2021;44:S111-S124.
    21. McMurray J. Presentation at: European Society of Cardiology Congress. September 1; 2019; Paris, France.

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes